A daily dose of clinical news on Patient Care you may have missed.
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
Last week, we reported on a study published in the BMJ journal Heart.
The study
An analysis of the Addiction In Intensive Cardiac Care Units (ADDICT-ICCU) study, which was designed to prospectively assess the prevalence of recreational drug use and its association with the occurrence of in-hospital major adverse events (MAEs). The observational study analyzed urine samples of all consecutive patients aged ≥18 years admitted to ICCUs across a 2-week period in April 2021 in France.
For the analysis, clinical outcomes included in-hospital MAEs defined as in-hospital death, resuscitated cardiac arrest, and hemodynamic shock requiring medical or mechanical hemodynamic support.
Within the study period, a total of 1904 patients were admitted to ICCUs in the 39 participating centers. After applying exclusion criteria, 1499 patients (95.2%) were screened using a urine drug assay (mean age, 63 years; 70% men).
The findings
Of the 1499 screened patients, 161 (11%) had a positive urine test for ≥1 recreational drug, including cannabis (9.1%), opioids (2.1%), cocaine (1.7%), amphetamines (0.7%), and MDMA (0.6%).
During hospitalization, there were 61 in-hospital MAEs (4.3%), including 25 (1.8%) in-hospital deaths, 10 (0.7%) cardiac arrests, and 26 (1.8%) hemodynamic shocks requiring hemodynamic support.
In multivariable analysis, the detection of recreational drug use was independently associated with in-hospital MAEs after adjusting for comorbidities (odds ratio [OR], 8.84; 95% CI, 4.68 - 16.7; P<.001). Compared with non drug-using heart patients, those who used recreational drugs showed a higher MAE rate, including hemodynamic shock and cardiac arrest, while in the hospital (13% vs. 3%; P<.001).
Authors' commentary
“Using a systematic urine assay, our study is the first to suggest a poorer in-hospital prognosis in those with detected recreational drugs in all consecutive patients admitted to ICCUs, which shows a potential interest in improving risk stratification of these patients."
AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.